The objective of this study is to evaluate the effect of diagnostic ureterorenoscopy (URS) prior to radical nephroureterectomy (RNU) on intravesical recurrence (IVR), in patients with primary upper urinary tract urothelial carcinoma (UTUC).
Urethral wall stents were introduced as a minimally invasive intervention for benign prostatic hyperplasia (BPH) in the 1990s. Despite reports of longer-term efficacy in select patients,1,2 challenges with recurrent occlusion and stent migration3-5 prevented widespread adoption of this technology. Over the past 10 years, however, novel designs and new materials have sparked renewed interest in […]
Background – To report the 3-year results of a prospective, single arm, multicenter, international clinical study with the second generation of the temporary implantable nitinol device (iTIND; Medi-Tate Ltd®, Israel) on men suffering lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO).
(UroToday.com) In a session of the Best Prostate Cancer Poster Presentations at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, Dr. Michael Schweizer presented there worked examining the role of apalutamide in lower-risk prostate cancer.
(UroToday.com) In the second Prostate Cancer session at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Maha Hussain discussed the role of poly ADP ribose polymerase (PARP) inhibitors, particularly olaparib, in metastatic castration-resistant prostate cancer.
(UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer.
(UroToday.com) At the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Dr. Maha Hussain presented the results of the PROfound study, Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study), which demonstrated the superiority of olaparib, a poly […]
(UroToday.com) In the second Prostate Cancer session at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Cora Sternberg provided an update on the PROSPER Trial, Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER). She began highlighting the background of patients with non-metastatic prostate cancer. Based on historical data, […]
(UroToday.com) In the session of the Best Prostate Cancer Poster Presentations at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Adam Weiner presented a population-based analysis examining the causes of death for men with prostate cancer. Given both the prevalence of prostate cancer and its high rates of survival, there is a large population […]
(UroToday.com) Dr. Peter Pinto began this session with an update on the comparison between MRI targeted vs. systematic prostate biopsy. The systematic prostate biopsy has a low sensitivity and specificity in detecting clinically significant prostate cancer (PCa). It may only sample 0.04% of the gland,1 and it has difficulty in sampling the anterior and apical regions.2 It is […]
